Amarin reported $612.88M in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
AbbVie USD 37.48B 3.81B Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amarin USD 612.88M 10.12M Sep/2026
AstraZeneca USD 31.45B 3.48B Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
DBV Technologies USD 189.6M 12.3M Sep/2026
GlaxoSmithKline GBP 17.9B 336M Sep/2026
Halozyme Therapeutics USD 1.85B 913.71M Sep/2026
Heron Therapeutics USD 209.11M 20.73M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Nektar Therapeutics USD 589.04M 322.77M Mar/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Novartis USD 28.75B 1.4B Sep/2026